Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
Maiden Holdings, Ltd. Announces First Quarter 2019 Financial Results – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Maiden Holdings, Ltd. Announces First Quarter 2019 Financial Results

Published

on

Reading Time: 12 minutes

PEMBROKE, Bermuda–(BUSINESS WIRE)–Maiden Holdings, Ltd. (NASDAQ:MHLD) (“Maiden” or the “Company”) today
reported a first quarter 2019 net loss attributable to Maiden common
shareholders of $36.6 million or $0.44 per diluted common share,
compared to a net income attributable to Maiden common shareholders of
$13.7 million or $0.16 per diluted common share in the first quarter of
2018. The non-GAAP operating loss(11) was $26.9 million, or
$0.32 per diluted common share compared with a non-GAAP operating income
of $5.8 million, or $0.07 per diluted common share in the first quarter
of 2018.

Maiden’s book value per common share(1) was $1.44 at
March 31, 2019, an increase of 33.3% from December 31, 2018.

Consolidated Results for the Quarter Ended
March 31, 2019

In the first quarter of 2019, gross premiums written were $(561.1)
million, compared to $623.3 million in the prior year quarter, primarily
due to the termination of both quota share contracts in the AmTrust
Reinsurance segment and the return of unearned premiums on certain lines
covered by the Partial Termination Agreement with AmTrust. As previously
reported, both terminations were effective January 1, 2019. Net premiums
earned were $183.1 million in first quarter 2019, compared to $516.8
million in first quarter 2018 due to the combined impact of the
terminated quota share contracts within the AmTrust Reinsurance segment
and non-renewals in Maiden’s European Capital Solutions business and a
reduction in the German Auto programs produced by the Company’s IIS unit
within its Diversified Reinsurance segment.

Advertisement
Stake.com

First quarter 2019 net loss and loss adjustment expenses decreased to
$152.7 million from $353.2 million in the first quarter of 2018, due
primarily to lower earned premiums for the AmTrust Reinsurance segment.
The first quarter 2019 loss ratio(6) was 83.0% compared to
67.9% reported in first quarter 2018. The increase in the loss ratio was
primarily due to a change in the mix of business resulting from the
Partial Termination Amendment entered into with AmTrust. Prior year
adverse loss development was $7.3 million for the first quarter of 2019,
compared to $9.8 million for the same period in 2018.

Commission and other acquisition expenses decreased to $69.6 million in
first quarter 2019, from $166.6 million in the first quarter of 2018 due
to significantly lower earned premiums resulting from the terminations
in the AmTrust Reinsurance segment. The commission and other acquisition
expense ratio increased 5.9 points to 37.9% for the first quarter of
2019 from 32.0% for the same period in 2018 as a result of the
additional ceding commission agreed to as part of the Partial
Termination Amendment with AmTrust.

General and administrative expenses for the first quarter of 2019
totaled $15.9 million, compared to $15.7 million in the first quarter of
2018. Non-recurring expenses were $3.0 million during the first quarter
of 2019, primarily related to salaries and related benefits for
headcount reductions occurring in 2019. The general and administrative
expense ratio(8) in the first quarter of 2019 increased to
8.7% from 3.0% in first quarter 2018 primarily as a result of lower
earned premiums, while the total expense ratio(9) was 46.6%
in first quarter 2019 compared with 35.0% for the same period last year.

The combined ratio(10) for first quarter 2019 totaled 129.6%,
compared with 102.9% in first quarter 2018.

First quarter 2019 net investment income decreased modestly to $32.0
million from $32.9 million in the first quarter of 2018 largely due to
the decline in average yield to 3.1% from 3.2% in the same period in
2018.

Advertisement
Stake.com

Additional information regarding the Company’s results of operations can
be found in the Company’s Quarterly Report on Form 10-Q filing made
concurrent with this news release.

Quarterly Dividends

The Company’s Board of Directors did not authorize any quarterly
dividends related to either its common shares or any series of its
preferred shares. Additional information regarding the Company’s
dividends can be found in the Company’s Quarterly Report on Form 10-Q
filing made concurrent with this news release.

Other Financial Matters

Total assets were $4.6 billion at March 31, 2019, compared to $5.3
billion at December 31, 2018. Shareholders’ equity was $584.3 million at
March 31, 2019, compared to $554.3 million at December 31, 2018.

Advertisement
Stake.com

(1)(11) Please see the Non-GAAP Financial Measures table for additional
information on these non-GAAP financial measures and reconciliation of
these measures to GAAP measures.

(6)(7)(8)(9)(10) Loss ratio, commission and other acquisition expense
ratio, general and administrative expense ratio, expense ratio and
combined ratio are non-GAAP operating metrics. Please see the additional
information on these measures under Non-GAAP Financial Measures tables.

About Maiden Holdings, Ltd.

Maiden Holdings, Ltd. is a Bermuda-based holding company formed in 2007.
The Company is focused on serving the needs of regional and specialty
insurers in Europe and select other global markets by providing
innovative reinsurance solutions designed to support their capital needs.

Forward Looking Statements

Advertisement
Stake.com

This release contains “forward-looking statements” which are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are based
on the Company’s current expectations and beliefs concerning future
developments and their potential effects on the Company. There can be no
assurance that actual developments will be those anticipated by the
Company. Actual results may differ materially from those projected as a
result of significant risks and uncertainties, including non-receipt of
the expected payments, changes in interest rates, effect of the
performance of financial markets on investment income and fair values of
investments, developments of claims and the effect on loss reserves,
accuracy in projecting loss reserves, the impact of competition and
pricing environments, changes in the demand for the Company’s products,
the effect of general economic conditions and unusual frequency of storm
activity, adverse state and federal legislation, regulations and
regulatory investigations into industry practices, developments relating
to existing agreements, heightened competition, changes in pricing
environments, and changes in asset valuations. In addition, the Company
may not be able to complete the proposed transaction with Enstar on the
terms summarized above or other acceptable terms, or at all, due to a
number of factors, including but not limited to failure to obtain
governmental and regulatory approvals or to satisfy other closing
conditions. Additional information about these risks and uncertainties,
as well as others that may cause actual results to differ materially
from those projected is contained in Item 1A. Risk Factors in the
Company’s Annual Report on Form 10-K for the year ended December 31,
2018 as updated in periodic filings with the SEC. However these factors
should not be construed as exhaustive. Forward-looking statements speak
only as of the date they are made and the Company undertakes no
obligation to update or revise any forward-looking statement that may be
made from time to time, whether as a result of new information, future
developments or otherwise, except as required by law.
       
Maiden Holdings, Ltd.
Consolidated Balance Sheets
(in thousands (000’s), except per share data)
 
March 31, 2019 December 31, 2018
(Unaudited) (Audited)
Assets

Fixed maturities, available-for-sale, at fair value (Amortized
cost 2019: $3,130,981 ; 2018:
$3,109,980)

$ 3,131,934 $ 3,051,568
Fixed maturities, held-to-maturity, at amortized cost (Fair value
2018: $998,012)
1,015,681
Other investments, at fair value   24,693   23,716
Total investments 3,156,627 4,090,965
Cash and cash equivalents 89,521 200,841
Restricted cash and cash equivalents 42,334 130,148
Accrued investment income 27,788 27,824
Reinsurance balances receivable, net 72,867 67,308
Loan to related party 167,975 167,975
Deferred commission and other acquisition expenses, net 161,976 388,442
Funds withheld receivable 652,087 27,039
Other assets 14,729 12,443
Assets held for sale   177,452   174,475
Total Assets $ 4,563,356 $ 5,287,460
Liabilities and Equity
Liabilities
Reserve for loss and loss adjustment expenses $ 2,980,113 $ 3,055,976
Unearned premiums 455,175 1,200,419
Reinsurance balances payable, net 117,943 52,594
Accrued expenses and other liabilities 12,087 12,900
Senior notes – principal amount 262,500 262,500
Less: unamortized debt issuance costs   7,753   7,806
Senior notes, net   254,747   254,694
Liabilities held for sale   159,002   155,961
Total Liabilities   3,979,067   4,732,544
Commitments and Contingencies
Equity
Preference Shares 465,000 465,000
Common shares 881 879
Additional paid-in capital 750,670 749,418
Accumulated other comprehensive loss (220) (65,616)
Accumulated deficit (600,527) (563,891)
Treasury shares, at cost   (31,515)   (31,515)
Total Maiden Shareholders’ Equity 584,289 554,275
Noncontrolling interest in subsidiaries     641
Total Equity   584,289   554,916
Total Liabilities and Equity $ 4,563,356 $ 5,287,460
 
 
Book value per common share(1) $ 1.44 $ 1.08
 
Common shares outstanding 83,064,173 82,948,577
 
 
Maiden Holdings, Ltd.
Consolidated Statements of Income
(in thousands (000’s), except per share data)
(Unaudited)
 
For the Three Months Ended March 31,

2019

2018

Revenues:
Gross premiums written $ (561,139) $ 623,328
Net premiums written $ (561,530) $ 622,651
Change in unearned premiums   744,632   (105,838)
Net premiums earned 183,102 516,813
Other insurance revenue 750 3,726
Net investment income 32,022 32,869
Net realized (losses) gains on investment (11,101) 357
Total revenues   204,773   553,765
Expenses:
Net loss and loss adjustment expenses 152,689 353,206
Commission and other acquisition expenses 69,617 166,628
General and administrative expenses   15,939   15,671
Total expenses   238,245   535,505
Non-GAAP (loss) income from operations(2)   (33,472)   18,260
Other expenses:
Interest and amortization expenses (4,829) (4,829)
Foreign exchange and other gains (losses)   4,979   (2,407)
Total other expenses   150   (7,236)
(Loss) income before income taxes (33,322) 11,024
Less: income tax benefit   (38)   (1,324)
Net (loss) income from continuing operations (33,284) 12,348
(Loss) income from discontinued operations, net of income tax   (3,352)   9,995
Net (loss) income (36,636) 22,343
Net income from continuing operations attributable to noncontrolling
interests
    (71)
Net (loss) income attributable to Maiden (36,636) 22,272
Dividends on preference shares(3)     (8,545)
Net loss attributable to Maiden common shareholders $ (36,636) $ 13,727

Basic (loss) earnings from continuing operations per share
attributable to Maiden common

shareholders

Advertisement
Stake.com
$ (0.40) $ 0.05

Basic (loss) earnings from discontinued operations per share
attributable to Maiden common

shareholders

  (0.04)   0.12
Basic (loss) earnings per share attributable to Maiden common
shareholders
$ (0.44) $ 0.17

Diluted (loss) earnings from continuing operations per share
attributable to Maiden common

shareholders(15)

$ (0.40) $ 0.04

Diluted (loss) earnings from discontinued operations per share
attributable to Maiden

common shareholders(15)

  (0.04)   0.12
Diluted (loss) earnings per share attributable to Maiden common
shareholders
(15)
$ (0.44) $ 0.16
Dividends declared per common share $ $ 0.15
Annualized return on average common equity -142.5% 7.6%
Weighted average number of common shares – basic 82,965,156 83,040,413
Adjusted weighted average number of common shares and assumed
conversions – diluted
(15)
82,965,156 83,318,542
 
                 
Maiden Holdings, Ltd.
Supplemental Financial Data – Segment Information
(in thousands (000’s))
(Unaudited)
 
 
 
 
For the Three Months Ended March 31, 2019

Diversified
Reinsurance

AmTrust
Reinsurance

Advertisement
Stake.com
Other Total
Gross premiums written $ 15,338 $ (576,477) $ $ (561,139)
Net premiums written $ 14,947 $ (576,477) $ $ (561,530)
Net premiums earned $ 25,292 $ 157,810 $ $ 183,102
Other insurance revenue 750 750
Net loss and loss adjustment expenses (“loss and LAE”) (14,391) (138,070) (228) (152,689)
Commissions and other acquisition expenses (9,261) (60,356) (69,617)
General and administrative expenses(4)   (3,031)   (1,266)     (4,297)
Underwriting loss(5) $ (641) $ (41,882) $ (228) $ (42,751)
 
Reconciliation to net loss from continuing operations
Net investment income and realized losses on investment 20,921
Interest and amortization expenses (4,829)
Foreign exchange and other gains 4,979
Other general and administrative expenses(4) (11,642)
Income tax benefit   38
Net loss from continuing operations $ (33,284)
 
 
Net loss and LAE ratio(6)   55.3%   87.5%   83.0%
Commission and other acquisition expense ratio(7) 35.6% 38.2% 37.9%
General and administrative expense ratio(8)   11.6%   0.8%   8.7%
Expense ratio(9)   47.2%   39.0%   46.6%
Combined ratio(10)   102.5%   126.5%   129.6%
 
 
 
 
For the Three Months Ended March 31, 2018

Diversified
Reinsurance

AmTrust
Reinsurance

Other Total
Gross premiums written $ 49,400 $ 573,928 $ $ 623,328
Net premiums written $ 48,271 $ 574,380 $ $ 622,651
Net premiums earned $ 25,515 $ 491,298 $ $ 516,813
Other insurance revenue 3,726 3,726
Net loss and LAE (15,899) (337,307) (353,206)
Commissions and other acquisition expenses (9,312) (157,316) (166,628)
General and administrative expenses(4)   (4,481)   (920)     (5,401)
Underwriting loss(5) $ (451) $ (4,245) $ $ (4,696)
 
Reconciliation to net income from continuing operations
Net investment income and realized gains on investment 33,226
Interest and amortization expenses (4,829)
Foreign exchange losses (2,407)
Other general and administrative expenses(4) (10,270)
Income tax benefit   1,324
Net income from continuing operations $ 12,348
 
Net loss and LAE ratio(6)   54.4%   68.7%   67.9%
Commission and other acquisition expense ratio(7) 31.8% 32.0% 32.0%
General and administrative expense ratio(8)   15.3%   0.2%   3.0%
Expense ratio(9)   47.1%   32.2%   35.0%
Combined ratio(10)   101.5%   100.9%   102.9%
 
     
Maiden Holdings, Ltd.
Non – GAAP Financial Measures
(in thousands (000’s), except per share data)
(Unaudited)
 
For the Three Months Ended March 31,
2019 2018
Non-GAAP operating (loss) income attributable to Maiden common
shareholders
(11)
$ (26,934) $ 5,782
Non-GAAP basic and diluted operating (loss) earnings per share
attributable to Maiden common shareholders
$ (0.32) $ 0.07
Annualized non-GAAP operating return on average common equity(12) -104.7% 3.2%
 

Reconciliation of net (loss) income attributable to Maiden
common shareholders to non-GAAP operating (loss)

income
attributable to Maiden common shareholders:

Net (loss) income attributable to Maiden common shareholders $ (36,636) $ 13,727
Add (subtract)
Net realized losses (gains) on investment 11,101 (357)
Foreign exchange and other (gains) losses (4,979) 2,407
Loss (income) from discontinued operations, net of income tax 3,352 (9,995)
Divested NGHC Quota Share run-off   228  
Non-GAAP operating (loss) income attributable to Maiden common
shareholders
(11)
$ (26,934) $ 5,782
 
Weighted average number of common shares – basic 82,965,156 83,040,413
Adjusted weighted average number of common shares and assumed
conversions – diluted
(15)
82,965,156 83,318,542
 

Reconciliation of diluted (loss) earnings per share
attributable to Maiden common shareholders to non-GAAP

diluted
operating (loss) earnings per share attributable to Maiden common
shareholders:

Diluted (loss) earnings per share attributable to Maiden common
shareholders
$ (0.44) $ 0.16
 
Add (subtract)
Net realized losses (gains) on investment 0.13
Foreign exchange and other (gains) losses (0.06) 0.03
Loss (income) from discontinued operations, net of income tax 0.04 (0.12)
Divested NGHC Quota Share run-off   0.01  
Non-GAAP diluted operating (loss) earnings per share attributable
to Maiden common shareholders
$ (0.32) $ 0.07
 
Reconciliation of net (loss) income attributable to Maiden to
non-GAAP (loss) income from operations:
Net (loss) income attributable to Maiden $ (36,636) $ 22,272
Add (subtract)
Foreign exchange and other (gains) losses (4,979) 2,407
Interest and amortization expenses 4,829 4,829
Income tax benefit (38) (1,324)

Loss (income) from discontinued operations, net of income tax

Advertisement
Stake.com

3,352

(9,995)

Net income attributable to noncontrolling interest

 

 

71

Advertisement
Stake.com
Non-GAAP (loss) income from operations(2) $ (33,472) $ 18,260
 
               
Maiden Holdings, Ltd.
Non – GAAP Financial Measures
(in thousands (000’s), except per share data)
(Unaudited)
 
 
 
March 31, 2019 December 31, 2018
Investable assets:
Total investments $ 3,156,627 $ 4,090,965
Cash and cash equivalents 89,521 200,841
Restricted cash and cash equivalents 42,334 130,148
Loan to related party 167,975 167,975
Funds withheld       652,087   27,039
Total investable assets(13) $     4,108,544 $ 4,616,968
 
March 31, 2019 December 31, 2018
Capital:
Preference shares $ 465,000 $ 465,000
Common shareholders’ equity       119,289   89,275
Total Maiden shareholders’ equity 584,289 554,275
2016 Senior Notes 110,000 110,000
2013 Senior Notes       152,500   152,500
Total capital resources(14) $     846,789 $ 816,775
 
(1) Book value per common share is calculated using Maiden common
shareholders’ equity (shareholders’ equity excluding the aggregate
liquidation value of our preference shares) divided by the number of
common shares outstanding.
 
(2) Non-GAAP (loss) income from operations is a non-GAAP financial
measure defined by the Company as net loss attributable to Maiden
excluding foreign exchange and other gains and losses, interest and
amortization expenses, income tax expense, net income or loss
attributable to noncontrolling interest and loss from discontinued
operations, net of income tax and should not be considered as an
alternative to net income (loss). The Company’s management believes
that non-GAAP (loss) income from operations is a useful measure of
the Company’s underlying earnings fundamentals based on its
underwriting and investment income before financing costs. This
(loss) income from operations enables readers of this information to
more clearly understand the essential operating results of the
Company. The Company’s measure of non-GAAP (loss) income from
operations may not be comparable to similarly titled measures used
by other companies.
 
(3) Dividends on preference shares consist of $0 and $3,094 paid to
Preference shares – Series A for the three months ended March 31,
2019 and 2018, respectively, $0 and $2,939 paid to Preference shares
– Series C for the three months ended March 31, 2019 and 2018,
respectively, and $0 and $2,512 paid to Preference shares – Series D
for the three months ended March 31, 2019 and 2018, respectively.
 
(4) Underwriting related general and administrative expenses is a
non-GAAP measure and includes expenses which are segregated for
analytical purposes as a component of underwriting income.
 
(5) Underwriting loss is a non-GAAP measure and is calculated as net
premiums earned plus other insurance revenue less net loss and LAE,
commission and other acquisition expenses and general and
administrative expenses directly related to underwriting activities.
Management believes that this measure is important in evaluating the
underwriting performance of the Company and its segments. This
measure is also a useful tool to measure the profitability of the
Company separately from the investment results and is also a widely
used performance indicator in the insurance industry.
 
(6) Calculated by dividing net loss and LAE by the sum of net
premiums earned and other insurance revenue.
 
(7) Calculated by dividing commission and other acquisition expenses
by the sum of net premiums earned and other insurance revenue.
 
(8) Calculated by dividing general and administrative expenses by
the sum of net premiums earned and other insurance revenue.
 
(9) Calculated by adding together the commission and other
acquisition expense ratio and general and administrative expense
ratio.
 
(10) Calculated by adding together the net loss and LAE ratio and
the expense ratio.
 
(11) Non-GAAP operating (loss) income is a non-GAAP financial
measure defined by the Company as net loss attributable to Maiden
common shareholders excluding realized and unrealized investment
gains and losses, foreign exchange and other gains and losses,
Divested NGHC Quota Share run-off and loss from discontinued
operations, net of income tax and should not be considered as an
alternative to net loss. The Company’s management believes that
non-GAAP operating (loss) income is a useful indicator of trends in
the Company’s underlying operations. The Company’s measure of
non-GAAP operating (loss) income may not be comparable to similarly
titled measures used by other companies.
 
(12) Non-GAAP operating return on average common equity is a
non-GAAP financial measure. Management uses non-GAAP operating
return on average common shareholders’ equity as a measure of
profitability that focuses on the return to Maiden common
shareholders. It is calculated using non-GAAP operating (loss)
income attributable to Maiden common shareholders divided by average
Maiden common shareholders’ equity.
 
(13) Investable assets is the total of the Company’s investments,
cash and cash equivalents, funds withheld receivable and loan to a
related party.
 
(14) Total capital resources is the sum of the Company’s principal
amount of debt and Maiden shareholders’ equity.
 
(15) During a period of loss, the basic weighted average common
shares outstanding is used in the denominator of the diluted loss
per common share computation as the effect of including potential
dilutive shares would be anti-dilutive.
 

Contacts

Sard Verbinnen & Co.
Maiden-SVC@sardverb.com


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania